Spain-based Almirall has named Peter Guenter as its new chief executive officer, it was reported yesterday.
The new chief executive officer is to succeed Eduardo Sanchiz, who leaves to dedicate more time to other interests.
Guenter joins from Sanofi, where he has worked for the past 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. He earlier held various senior positions at Sanofi, including vice president Eastern Europe and Northern Europe, vice president business management and support, general manager, Germany, and senior vice president, Europe.
Sanchiz will hand over the Almirall leadership to Guenter during September.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China